JP2009538318A - 併用療法において免疫調節化合物を用いる方法及び組成物 - Google Patents

併用療法において免疫調節化合物を用いる方法及び組成物 Download PDF

Info

Publication number
JP2009538318A
JP2009538318A JP2009512164A JP2009512164A JP2009538318A JP 2009538318 A JP2009538318 A JP 2009538318A JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009538318 A JP2009538318 A JP 2009538318A
Authority
JP
Japan
Prior art keywords
amino
dione
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538318A5 (es
Inventor
ベルヘルレ ドミニクエ
チャン クイレ
クオルラル ラウラ
モウトウフ デ パルセバル ラウレ
ブラドイ ヘレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2009538318A publication Critical patent/JP2009538318A/ja
Publication of JP2009538318A5 publication Critical patent/JP2009538318A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009512164A 2006-05-26 2007-05-24 併用療法において免疫調節化合物を用いる方法及び組成物 Pending JP2009538318A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
PCT/US2007/012495 WO2007139939A2 (en) 2006-05-26 2007-05-24 Methods and compositions using immunomodulatory compounds in combination therapy

Publications (2)

Publication Number Publication Date
JP2009538318A true JP2009538318A (ja) 2009-11-05
JP2009538318A5 JP2009538318A5 (es) 2010-07-29

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512164A Pending JP2009538318A (ja) 2006-05-26 2007-05-24 併用療法において免疫調節化合物を用いる方法及び組成物

Country Status (11)

Country Link
EP (1) EP2023912A2 (es)
JP (1) JP2009538318A (es)
KR (1) KR20090014393A (es)
CN (1) CN101495111A (es)
AU (1) AU2007267928A1 (es)
CA (1) CA2652888A1 (es)
IL (1) IL195412A0 (es)
MX (1) MX2008014912A (es)
RU (1) RU2426542C2 (es)
WO (1) WO2007139939A2 (es)
ZA (1) ZA200809956B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510983A (ja) 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
EP2827869A4 (en) * 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
CN105579101A (zh) 2013-08-22 2016-05-11 万达制药公司 癌症的治疗
MX2016002308A (es) 2013-08-22 2016-06-15 Vanda Pharmaceuticals Inc Tratamiento del mieloma multiple.
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
WO2023034504A1 (en) * 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507767A (ja) * 1993-03-01 1996-08-20 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 管脈形成を抑制する方法および組成物
JP2005530784A (ja) * 2002-05-17 2005-10-13 セルジーン・コーポレーション 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物
JP2006500911A (ja) * 2002-04-12 2006-01-12 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
JP2006507284A (ja) * 2002-10-24 2006-03-02 セルジーン・コーポレーション 疼痛を治療、改変および管理するための免疫調節化合物の使用方法および組成物
JP2006507325A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患の治療および管理のための免疫調節化合物を含む使用方法および組成物
JP2007513164A (ja) * 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507767A (ja) * 1993-03-01 1996-08-20 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン 管脈形成を抑制する方法および組成物
JP2006500911A (ja) * 2002-04-12 2006-01-12 セルジーン・コーポレーション 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用
JP2005530784A (ja) * 2002-05-17 2005-10-13 セルジーン・コーポレーション 癌および他の疾患を治療および管理するための免疫調節性化合物を用いた方法および組成物
JP2006507284A (ja) * 2002-10-24 2006-03-02 セルジーン・コーポレーション 疼痛を治療、改変および管理するための免疫調節化合物の使用方法および組成物
JP2006507325A (ja) * 2002-11-06 2006-03-02 セルジーン・コーポレーション 骨髄増殖性疾患の治療および管理のための免疫調節化合物を含む使用方法および組成物
JP2007513164A (ja) * 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012054646; ＧＯＲＥ，Ｓ．Ｄ．: 'Ｃｏｍｂｉｎａｔｉｏｎ　ｔｈｅｒａｐｙ　ｗｉｔｈ　ＤＮＡ　ｍｅｔｈｙｌｔｒａｎｓｆｅｒａｓｅ　ｉｎｈｉｂｉｔｏｒｓ　ｉｎ　ｈｅｍａｔｏｌｏｇｉｃ　ｍａｌｉｇｎａｎｃｉｅｓ' Ｎａｔ　Ｃｌｉｎ　Ｐｒａｃｔ　Ｏｎｃｏｌ Ｖｏｌ．２　Ｓｕｐｐｌ　１, 2005, ｐ．Ｓ３０-５ *
JPN6012054647; ＭＡＲＩＡＮＮＡ，Ｐ．　ｅｔ　ａｌ: 'Ｖａｌｐｒｏｉｃ　ａｃｉｄ，　ｔｒｉｃｈｏｓｔａｔｉｎ　ａｎｄ　ｔｈｅｉｒ　ｃｏｍｂｉｎａｔｉｏｎ　ｗｉｔｈ　ｈｅｍｉｎ　ｐｒｅｆｅｒｅｎｔｉａｌｌｙ　ｅｎｈａｎｃｅ　ｇａｍｍａ-ｇｌｏｂｉｎ　ｇｅｎ' Ｈａｅｍａｔｏｌｏｇｉｃａ Ｖｏｌ．８６，　Ｎｏ．７, 2001, ｐ．７００-５ *
JPN6012054650; ＤＥ，Ｆ．Ｅ．　ｅｔ　ａｌ: 'Ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　ｉｎｈｉｂｉｔｏｒ　ｖａｌｐｒｏｉｃ　ａｃｉｄ　ｅｎｈａｎｃｅｓ　ｔｈｅ　ｃｙｔｏｋｉｎｅ-ｉｎｄｕｃｅｄ　ｅｘｐａｎｓｉｏｎ　ｏｆ　ｈｕｍａｎ　ｈｅｍａｔｏｐ' Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６５，　Ｎｏ．４, 2005, ｐ．１５０５-１３ *
JPN6012054651; ＢＵＧ，Ｇ．　ｅｔ　ａｌ: 'Ｖａｌｐｒｏｉｃ　ａｃｉｄ　ｓｔｉｍｕｌａｔｅｓ　ｐｒｏｌｉｆｅｒａｔｉｏｎ　ａｎｄ　ｓｅｌｆ-ｒｅｎｅｗａｌ　ｏｆ　ｈｅｍａｔｏｐｏｉｅｔｉｃ　ｓｔｅｍ　ｃｅｌｌｓ' Ｃａｎｃｅｒ　Ｒｅｓ Ｖｏｌ．６５，　Ｎｏ．７, 2005, ｐ．２５３７-４１ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
JP2020124212A (ja) * 2014-03-26 2020-08-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Also Published As

Publication number Publication date
WO2007139939A2 (en) 2007-12-06
MX2008014912A (es) 2008-12-10
RU2008151713A (ru) 2010-07-10
CA2652888A1 (en) 2007-12-06
CN101495111A (zh) 2009-07-29
IL195412A0 (en) 2009-08-03
EP2023912A2 (en) 2009-02-18
RU2426542C2 (ru) 2011-08-20
ZA200809956B (en) 2010-07-28
WO2007139939A3 (en) 2008-07-03
KR20090014393A (ko) 2009-02-10
AU2007267928A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
AU2004296765B2 (en) Methods and compositions for the treatment and management of hemoglobinopathy and anemia
JP4481828B2 (ja) 骨髄異形成症候群を治療および管理するための免疫調節化合物の使用方法およびそれを含む組成物
US20060154880A1 (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
RU2426542C2 (ru) Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении
US20080199422A1 (en) Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
AU2014202561B2 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
NZ550831A (en) 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione or CC-4047 for the treatment and management of myelodysplastic syndromes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507